14-3-3 phosphorylation in Parkinson's disease
14-3-3 phosphorylation in Parkinson's disease
批准号:
10630910
负责人:
Talene Alene Yacoubian
金额:
$39.56万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-09-15 至 2025-05-31
关键词:
AffectBindingBiological AssayBrainCell CommunicationCellsClinicalDataDementia with Lewy BodiesDetergentsDiseaseDisease ProgressionDisinhibitionEventFunctional disorderGenesGoalsHumanIdiopathic Parkinson DiseaseImmunoprecipitationImpaired cognitionImpairmentInterventionKnock-inKnock-in MouseLRRK2 geneLeadLewy Body DiseaseLigationLinkMeasuresMediatingMitochondriaModelingMolecular ChaperonesMusMutationNerve DegenerationNeurodegenerative DisordersNeuronal InjuryNeurotoxinsOutcomeOxidative StressOxidative Stress InductionParkinson DiseasePathogenesisPathologicPathologyPatientsPesticidesPhosphorylationPhosphotransferasesProcessProtein IsoformsProteinsPublishingResearchRiskRisk FactorsRoleRotenoneSeveritiesStressSurface Plasmon ResonanceTestingToxic effectToxinVariantalpha synucleinautosomebrain tissuegenome wide association studyin vivolink proteinmimeticsmouse modelmutantneurotoxicitynovelparacrinepre-clinicalpreventprotective effectprotein transportresponsesporadic Parkinson&aposs Diseasetherapeutic targettooltransmission process
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Two critical proteins linked to Parkinson’s disease (PD) are alpha-synuclein (αsyn) and LRRK2. Mutations in
either gene cause autosomal dominant forms of PD, and GWAS studies have pointed to variants in both genes
as risk factors for developing idiopathic PD. Although both proteins lead to a similar pathological outcome, how
these two proteins cause neuronal injury and how they interact in the disease process are not well understood.
Our key discovery is that 14-3-3θ is a major regulator of both αsyn and LRRK2 and could be the missing link
between αsyn and LRRK2. 14-3-3s are multifunctional, highly expressed brain proteins that act as chaperones,
affect protein trafficking, and modulate enzymatic activity of their binding partners. Our research has highlighted
the role of these critical proteins in PD and their interplay with both αsyn and LRRK2. We have observed that
14-3-3θ acts as a chaperone to reduce αsyn aggregation and cell-to-cell transmission, and this same 14-3-3
isoform reduces the kinase activity and toxicity of mutant LRRK2.
While our data clearly points to a potentially critical role for 14-3-3 dysfunction in Parkinson’s disease, a key
question that remains is how 14-3-3θ’s endogenous functions could become impaired in PD. We propose that
aberrant phosphorylation of 14-3-3θ is the critical pathophysiologic event, and that increases in 14-3-3θ
phosphorylation promotes LRRK2 and αsyn effects in disease. In support of this hypothesis, we recently
published data showing that 14-3-3θ phosphorylation at S232 is dramatically elevated in the detergent-insoluble
fractions from human PD and DLB brains. This increase in S232 phosphorylation correlates with cognitive
decline and pathological severity measures, consistent with a role of S232 phosphorylation in the pathogenesis
of neurodegeneration. In addition, we have observed that mitochondrial stress promotes 14-3-3θ
phosphorylation at S232 in culture. The S232D phosphomimetic mutant loses its protective effects in neurotoxin
and αsyn culture models.
Based on these data, we hypothesize that oxidative stress is a key upstream inducer of excessive 14-3-3θ
phosphorylation, leading to αsyn and LRRK2 toxicity. We recently created a conditional knock-in (KI) 14-3-3θ
S232D mouse line that will serve as the critical tool to understand the impact of 14-3-3 phosphorylation in PD.
In Aim 1, we will test how 14-3-3θ phosphorylation alters interactions with αsyn and modulates subsequent αsyn
pathology. In Aim 2, we will test the impact of 14-3-3 phosphorylation on its interaction with LRRK2 and LRRK2
function. In Aim 3, we will examine whether 14-3-3θ phosphorylation occurs early in sporadic PD and whether
oxidative stress mediates toxicity via excessive 14-3-3 phosphorylation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of Rab27b in synucleinopathies
-
批准号:10204274
-
项目类别:
-
资助金额:$43.07万
-
财政年份:2020
-
负责人:Talene Alene Yacoubian
-
依托单位:
14-3-3 phosphorylation in Parkinson's disease
-
批准号:10882853
-
项目类别:
-
资助金额:$1.2万
-
财政年份:2019
-
负责人:Talene Alene Yacoubian
-
依托单位:
14-3-3 phosphorylation in Parkinson's disease
-
批准号:10621515
-
项目类别:
-
资助金额:$7.19万
-
财政年份:2019
-
负责人:Talene Alene Yacoubian
-
依托单位:
14-3-3 phosphorylation in Parkinson's disease
-
批准号:10621461
-
项目类别:
-
资助金额:$7.19万
-
财政年份:2019
-
负责人:Talene Alene Yacoubian
-
依托单位:
14-3-3 phosphorylation in Parkinson's disease
-
批准号:10407523
-
项目类别:
-
资助金额:$40.77万
-
财政年份:2019
-
负责人:Talene Alene Yacoubian
-
依托单位:
14-3-3 phosphorylation in Parkinson's disease
-
批准号:10199080
-
项目类别:
-
资助金额:$39.71万
-
财政年份:2019
-
负责人:Talene Alene Yacoubian
-
依托单位:
14-3-3 phosphorylation in Parkinson's disease
-
批准号:9797123
-
项目类别:
-
资助金额:$43.38万
-
财政年份:2019
-
负责人:Talene Alene Yacoubian
-
依托单位:
14-3-3 phosphorylation in Parkinson's disease
-
批准号:10660102
-
项目类别:
-
资助金额:$7.19万
-
财政年份:2019
-
负责人:Talene Alene Yacoubian
-
依托单位:
14-3-3 phosphorylation in Parkinson's disease
-
批准号:10006597
-
项目类别:
-
资助金额:$39.19万
-
财政年份:2019
-
负责人:Talene Alene Yacoubian
-
依托单位:
Core B: Clinical Research Core
-
批准号:10469385
-
项目类别:
-
资助金额:$31.86万
-
财政年份:2018
-
负责人:Talene Alene Yacoubian
-
依托单位:
Core B: Clinical Research Core
-
批准号:9976621
-
项目类别:
-
资助金额:$51.12万
-
财政年份:2018
-
负责人:Talene Alene Yacoubian
-
依托单位:
Southeastern Medical Scientist Symposium
-
批准号:10090610
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2017
-
负责人:Talene Alene Yacoubian
-
依托单位:
Regulation of cellular release of proteins in Parkinson neurodegeneration
-
批准号:8894628
-
项目类别:
-
资助金额:$32.48万
-
财政年份:2014
-
负责人:Talene Alene Yacoubian
-
依托单位:
Southeastern Medical Scientist Symposium
-
批准号:10537009
-
项目类别:
-
资助金额:$0.75万
-
财政年份:2014
-
负责人:Talene Alene Yacoubian
-
依托单位:
Regulation of cellular release of proteins in Parkinson neurodegeneration
-
批准号:9336978
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2014
-
负责人:Talene Alene Yacoubian
-
依托单位:
Southeastern Medical Scientist Symposium
-
批准号:10705270
-
项目类别:
-
资助金额:$0.75万
-
财政年份:2014
-
负责人:Talene Alene Yacoubian
-
依托单位:
Regulation of cellular release of proteins in Parkinson neurodegeneration
-
批准号:9119881
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2014
-
负责人:Talene Alene Yacoubian
-
依托单位:
Regulation of cellular release of proteins in Parkinson neurodegeneration
-
批准号:8764591
-
项目类别:
-
资助金额:$32.57万
-
财政年份:2014
-
负责人:Talene Alene Yacoubian
-
依托单位:
Role of 14-3-3 Proteins in Alpha-Synuclein-Induced Neurotoxicity
-
批准号:8220941
-
项目类别:
-
资助金额:$16.82万
-
财政年份:2008
-
负责人:Talene Alene Yacoubian
-
依托单位:
Role of 14-3-3 Proteins in Alpha-Synuclein-Induced Neurotoxicity
-
批准号:8034704
-
项目类别:
-
资助金额:$16.82万
-
财政年份:2008
-
负责人:Talene Alene Yacoubian
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: